3rd Quarter - Report
LMH STRATEGIC SOLUTIONS for IONIS PHARMACEUTICALS, INC.
Client
Income
$30,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALANNA TEMME | Legislative Director, U.S. Representative Jon Porter |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.